Genetic Technologies and CancerIQ: A Collaborative Approach to Innovation
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE), a respected player in the world of genomics-based testing, has recently teamed up with CancerIQ, a company based in Chicago. This partnership is designed to boost cancer prevention efforts by enabling healthcare organizations and clinics to more effectively identify patients at high risk.
The Role of CancerIQ in Improving Patient Care
Over the years, CancerIQ has made considerable progress, especially in breast imaging, where its platform has been integrated into clinical operations. This integration has resulted in a significant increase in genetic testing adoption. Consequently, clinics can prioritize patients who are at greater risk and ensure they receive timely cancer prevention screenings.
Enhancing Risk Assessment Models
Historically, CancerIQ has focused on conventional risk assessment models and standard germline testing for hereditary risks. With the introduction of Genetic Technologies' geneType Risk Assessment Test, there’s a clear move toward primary preventive care. Together, both companies are dedicated to equipping healthcare providers with in-depth risk assessments, enabling tailored cancer prevention strategies.
Innovative Approaches with GeneType
GeneType is CancerIQ’s first laboratory partner specializing in polygenic-integrated clinical risk prediction. This partnership marks an important shift in population healthcare, moving beyond a narrow focus on hereditary cancer risks to address multiple major diseases, including various cancers and cardiometabolic conditions.
Adapting Business Strategies
In response to challenges in today's commercial landscape, the companies are transitioning to a commission-based, contract-only sales model. This strategy aims to streamline operations, reduce overhead costs, and improve visibility within U.S. healthcare systems that currently utilize CancerIQ.
Engagement with U.S. Healthcare Providers
Through this collaboration, GeneType is set to enhance its presence among more than 45 healthcare systems and over 250 clinics throughout the U.S. A significant number of these facilities specialize in primary care and breast health, placing GeneType in a strong position to thrive. So far, over 1 million patients have been screened using the CancerIQ platform, highlighting its broad acceptance.
Simplifying the Test Ordering Process
Committed to improving efficiency, GeneType is set to join CancerIQ’s Premium Tier for an annual fee. This integration will streamline the test ordering process by automatically including GeneType in the healthcare professional's test menu and prepopulating the GeneType Test Request Form, creating a smoother experience for both healthcare providers and patients.
Looking Ahead: The Future of Cancer Risk Assessment
Peter Rubinstein, Chairman of GENE, expressed his excitement about this partnership, highlighting its potential to make geneType Risk Assessment Tests more accessible in the medical community. This collaboration is also expected to open up co-marketing opportunities that will raise awareness about population risk assessment methods.
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) has gained a robust reputation as a diversified molecular diagnostics firm. The company plays a crucial role in promoting genomics-based testing aimed at health, wellness, and serious diseases. Through its established brands, geneType and EasyDNA, GTG provides predictive testing and assessment tools that assist healthcare providers worldwide in enhancing health outcomes.
Frequently Asked Questions
What’s the importance of the partnership between Genetic Technologies and CancerIQ?
This collaboration boosts cancer prevention efforts by incorporating advanced risk assessment tools that help healthcare providers identify and prioritize patients with a higher risk.
How will geneType's integration help clinical practices?
By incorporating geneType into the CancerIQ platform, test ordering becomes simpler, and healthcare professionals can perform more comprehensive risk assessments efficiently.
What challenges does Genetic Technologies face in the commercial sector?
The company has encountered slow sales cycles and limited commercial reach, prompting a shift to a commission-based sales strategy for a greater impact.
What are the expected outcomes of this partnership?
The collaboration aims to make cancer risk assessments more accessible, ultimately helping to improve health outcomes for patients.
How many patients have used the CancerIQ platform?
Over 1 million patients have been screened through the CancerIQ platform, showcasing its effectiveness in practical scenarios.
